5

5 Schedule

The schedule to this instrument sets out the direction given to the Pricing Authority on the performance of its functions and exercise of its powers.

Schedule

1 Function

The Pricing Authority, in relation to the performance of its functions under paragraphs 131(1)(h)–(i) and (n) of the Act, is directed to undertake a costing and pricing study into the NFC Program.

2 Matters Pricing Authority to study

In carrying out the study, the Pricing Authority is directed to inquire into and make findings about the following matters: (a) the direct and indirect cost of providing each NFC service at each specified site for that NFC service; (b) the aggregate direct and indirect cost of providing each NFC service across all specified sites for that NFC service; (c) the projected cost of providing all NFC services at all specified sites; and (d) the existing direct and indirect cost of providing each NFC service for each patient in each specified site for that NFC service.

3 Pricing Authority to recommend options

In carrying out the study, the Pricing Authority must recommend options in respect of the following matters: (a) whether NFC services, individually and collectively, are more appropriately funded via Activity Based Funding (ABF) or block funding arrangements under the National Health Reform Agreement; (b) the development and operation of cost models and pricing models for the NFC Program, covering both existing and potential future services delivered under the NFC Program; and (c) other related matters deemed appropriate by the Pricing Authority.

4 Pricing Authority must have regard to particular matters

In carrying out the study, the Pricing Authority must have regard to the following: (a) the National Health Reform Agreement; (b) NFC program cost and activity data supplied by a State or Territory; (c) any submissions regarding the study to the Pricing Authority from: (i) the Commonwealth; (ii) a State or Territory; (iii) public hospitals; (iv) other health bodies; and (v) other parties deemed relevant by the Pricing Authority; and (d) other related matters deemed appropriate by the Pricing Authority.

5 NFC services and specified sites

For the purposes of section 2, at the time this direction is issued: (a) a service mentioned in column 1 of an item in the following table is specified as a NFC service; and (b) a site mentioned in column 2 of the item is specified for the particular NFC service in column 1.

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="3" style="border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableHeading"><span style="font-size:11pt">Specified </span><span style="font-size:11pt">service</span><span style="font-size:11pt"> and sites</span></p></td></tr><tr><td style="width:8.58%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableHeading"><span style="font-size:11pt">Item</span></p></td><td style="width:45.7%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableHeading"><span style="font-size:11pt">Column 1</span></p><p class="TableHeading"><span style="font-size:11pt">Service</span><span style="font-size:11pt"></span></p></td><td style="width:45.72%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableHeading"><span style="font-size:11pt">Column 2</span></p><p class="TableHeading"><span style="font-size:11pt">Site</span></p></td></tr></thead><tbody><tr><td style="width:8.58%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">1</span></p></td><td style="width:45.7%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">Islet cell transplantation for the treatment of severe hypoglycaemia unawareness and metabolic instability in </span><span style="font-size:11pt">p</span><span style="font-size:11pt"> with Type-1 diabetes</span></p></td><td style="width:45.72%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea" style="font-size:11pt"><span>(a) </span><span>Royal Adelaide Hospital, South Australia</span></p><p class="Tablea" style="font-size:11pt"><span>(b) </span><span>St. Vincent’s Hospital, Victoria</span></p><p class="Tablea" style="font-size:11pt"><span>(c) </span><span>Westmead Hospital</span><span>, New South Wales</span></p></td></tr><tr><td style="width:8.58%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">2</span></p></td><td style="width:45.7%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">Paediatric heart transplantation</span></p></td><td style="width:45.72%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea" style="font-size:11pt"><span>(a) </span><span>Royal Children’</span><span>s Hospital</span><span>, Victoria</span></p></td></tr><tr><td style="width:8.58%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">3</span></p></td><td style="width:45.7%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">Paediatric liver transplantation</span></p></td><td style="width:45.72%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea" style="font-size:11pt"><span>(a) </span><span>Queensland Children's Hospita</span><span>l</span><span>, Queensland</span></p><p class="Tablea" style="font-size:11pt"><span>(b) </span><span>Royal Children’s Hospital</span><span>, Victoria</span></p><p class="Tablea" style="font-size:11pt"><span>(c) </span><span>The Sydney Children’s Hospitals</span><span> Netw</span><span>ork (Westmead), New South Wales</span></p></td></tr><tr><td style="width:8.58%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">4</span></p></td><td style="width:45.7%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">Paediatric lung and heart-lung transplantation</span></p></td><td style="width:45.72%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea" style="font-size:11pt"><span>(a) </span><span>Alfred Hospital</span><span>, Victoria</span></p></td></tr><tr><td style="width:8.58%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">5</span></p></td><td style="width:45.7%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt">Pancreas transplantation</span></p></td><td style="width:45.72%; border-top:0.75pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea" style="font-size:11pt"><span>(a) </span><span>Monash Medical Centre, Victoria</span></p><p class="Tablea" style="font-size:11pt"><span>(b) </span><span>Westmead Ho</span><span>spital</span><span>, New South Wales</span></p></td></tr></tbody></table>

6 Other matters

The Pricing Authority is directed to: (a) commence the study as soon as practicable; (b) provide updates about the study to the Australian Health Ministers’ Advisory Council and the Standing Council on Health as requested; (c) provide an interim report of the results of the study and options to the Australian Health Ministers’ Advisory Council, not later than 1 August 2020; and (d) submit to the Standing Council on Health a final report of the results of the study and options, not later than 31 January 2021.